

FORM PTO/SB/08A
(REV. 10-96)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Sheet 1 of 2

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Complete if Known

Application Number:	09/994,923
Filing Date:	28 November 2001
First Named Inventor:	LAW, William R.
Group Art Unit	1623
Examiner Name	Lawrence E. CRANE
Attorney Docket Number:	21726/92990

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
@@	A.1	3,923,785	Dec. 02, 1975	Ryder et al.	
@@	A.2	4,400,387	Aug. 23, 1983	Rosseels et al.	
@@	A.3	5,463,035	Oct. 31, 1995	French et al.	
@@	A.4	5,646,128	July 08, 1997	Firestein et al.	
@@	A.5	5,703,084	Dec. 30, 1997	Abushanab et al.	
@@	A.6	5,731,432	Mar. 24, 1998	Erion et al.	
**	A.7	WO 00/05217	Feb. 03, 2000		
<div>RECEIVED</div> <div>SEP 10 2002</div> <div>TECH CENTER 1600/2900</div>					

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

EXAMINER

L. E. Crane

DATE CONSIDERED

03/18/03

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Send to: Assistant Commissioner for Patents, Washington, D.C. 20231.

** Incorrect citation (not a US patent); see PTO-892 for correct citation.

@ Duplicate citation: see PTO-892 for original citation.

FORM PTO/SB/08A
(REV. 10-96)

SEP 06 2002

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Substitute for form 1449 PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

Sheet 2 of 2

Complete if Known

Application Number	09/994,923
Filing Date	28 November 2001
First Named Inventor	LAW, William R.
Group Art Unit	1623
Examiner Name	Lawrence E. CRANE
Attorney Docket Number	21726 92990

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>JEC</i>	A8 !	ALBERT, D.A., et al. (1996) "Deoxycorymycin (Pentostatin) for the treatment of rheumatoid arthritis." JOURNAL OF INVESTIGATIVE MEDICINE, US, AMERICAN FEDERATION FOR CLINICAL RESEARCH. 44(2): 330A.	
	A9 !	BEERS, M.H. and BERKOW, R. (1999) "The Merck Manual of Diagnosis and Therapy, Seventeenth Edition." MERCK RESEARCH LABORATORIES, WHITEHOUSE STATION, NEW YORK. 1143-1145.	
	A10	BOUMA, M.G., et al. (1996) "Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells." American Journal of Physiology, 270(2, Pt. 1), C522-C529 (February, 1996).	
	A11	BOUMA, M.G., et al. (1994) "Differential Regulatory Effects of Adenosine on Cytokine Release by Activated Human Monocytes." Journal of Immunology, 153(9), 4159-4168(11/01/1994).	
	A12 !	GUSTIN, N.C. and KEMP, R.G. (1976) "A Rapid, Sensitive Assay for Adenosine Deaminase." ANALYTICAL BIOCHEMISTRY. 71: 527-532.	
	A13 !	JOHNSTON, J.B., et al. (1992) "Induction of Apoptosis in CD4+ Polymorphocytic Leukemia by Deoxyadenosine and 2'-Deoxycorymycin." Leukemia Research, 16(8): 781-788.	
	A14	LE MOINE, O., et al. (1999) "Blunted anti-inflammatory response to adenosine in alcoholic cirrhosis." JOURNAL OF HEPATOLOGY. 31: 457-463. (September, 1999).	
	A15 !	MEADOW, W.L. and MEUS, P.J. (1985) "Nonhomogeneous Redistribution of Mesenteric Blood Flow after Tolazoline during Group B Streptococcal Sepsis in Piglets." DEV. PHARMACOL. Ther., 8, 209-218 (1985).	
	A16	MOTEW, S.J., et al. (1997) "Evidence that Adenosine Contributes to Maintenance of Hepatosplanchnic Blood Flow During Peritoneal Sepsis in Rats." SHOCK. 7(6): 439-446(June, 1997).	
	A17	MOTEW, S.J., et al. (1998) "Adenosine Receptor Antagonism Affects Regional Resting Vascular Resistance during Rat Peritoneal Sepsis." JOURNAL OF SURGICAL RESEARCH. 80: 326-332. (December, 1998).	
	A18 !	OGILVIE, A.C., et al. (1991) "Plasma lipid peroxide and antioxidants in human septic shock." INTENSIVE CARE MED. 17: 40-44.	
	A19	POPLACK, D.G., et al. (1981) "Phase I Study of 2'-Deoxycorymycin in Acute Lymphoblastic Leukemia." CANCER RESEARCH. 41: 3343-3346. (September, 1981).	
<i>JEC</i>	A20 !	SCHAEFFER, H.J. and SCHWENDER, C.F. (1974) "Enzyme Inhibitors. 26. Bridging Hydrophobic and Hydrophilic Regions on Adenosine Deaminase with Some 9-(2-Hydroxy-3-alkyl) adenines." JOURNAL OF MEDICINE CHEMISTRY. 17(1): 6-8.	

EXAMINER	L. E. Crane <i>J E Crane</i>	DATE CONSIDERED	03/18/03
----------	------------------------------	-----------------	----------

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231

! Month of publication data could not be determined from the copy supplied.

COPY FOR [] File (2) Applicant

RECEIVED

SEP 10 2002

TECH CENTER 1600/2900

FORM PTO/SB/08A
(REV. 10-96)

Substitute for form 1449A/P

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

Sheet 1 of 1

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Complete if Known

Application Number	09/994,923
Filing Date	28 November 2001
First Named Inventor	LAW, William R.
Group Art Unit	1623
Examiner Name	Lawrence E. CRANE
Attorney Docket Number	21726 92990

A

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*

Cite
No.¹

Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

T²

A.21

PRAGNACHARYULU, P.V.P., et al. (2000) "Adenosine Deaminase Inhibitors: Synthesis and Biological Evaluation of Unsaturated, Aromatic, and Oxo Erivatives of (+)-erythro-9-(2'S-Hydroxy-3'R-nonyl)adenine [(+)-EHNA]." *J. Med. Chem.* 43 4694-4700. (November, 10, 2000).

A.2

A.3

A.4

A.5

A.6

A.7

A.8

A.9

A.10

A.11

A.12

A.13

RECEIVED
SEP 25 2002
TECH CENTER 1600/2900

EXAMINER

L. E. Crane

DATE CONSIDERED

03/18/03

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231

09/994,923 - PTO-1449 #2

COPY FOR [] File ☒ Applicant